The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a strategic shift toward high-growth specialty medicines, analysts have reaffirmed a bullish outlook on Sanofi following robust performance in its core drug portfolio. According to reports, Dupixent sales surged 30.8% to $4.85 billion in the first quarter of 2026, a growth trajectory fueled by successful pediatric market penetration. Additionally, Sarclisa sales rose by 30.1% to $193.21 million, underscoring the company's strengthening position in the oncology segment.
This growth comes as major pharmaceutical players intensify their competition in the immunology and oncology spaces, with Sanofi leveraging innovations like the new on-body injector for Sarclisa to gain ground in the multiple myeloma market. Per market data, Dupixent's growth rate remains a standout compared to peers like Novartis in the immunology sector. Analysts suggest that this Q1 execution provides a solid buffer against broader macroeconomic volatility and rising operational costs seen across the industry.
Sign in to access this content
Sign InInvestors should watch key price levels as SAN.PA closed at 75.54 EUR and SNY at 43.8 USD (close June 15, 2026). Looking ahead, market sentiment may be influenced by upcoming economic catalysts, including global inflation trends which recently saw US CPI at 4.2%. The continued clinical and commercial scaling of Dupixent remains the primary catalyst for Sanofi's valuation as the company heads into the second half of the fiscal year.